TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley

Update: 2025-09-16

Description

As we now have funded 2nd line access to TDXD (ENHERTU) in the treatment of HER2 + Gastric and GEJ cancer after Trastuzumab containing regimens, Dr. Christine Brezden-Masley takes us through the regimen, its use and efficacy and toxicity management

Comments

In Channel

BREAKWATER: Charting New Waters in Advanced BRAFmt CRC with Dr. Rachel Goodwin

2025-11-2434:54

Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak

2025-10-0732:58

TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley

2025-09-1636:13

Check or Checkmate Ipi/Nivo in HCC with Dr. Hatim Karachiwala

2025-09-1132:53

IPI/NIVO for mCRC with Dr. Sharlene Gill

2025-08-2133:23

The CHALLENGE to Move and Survive: Exercise After Adjuvant Colon Cancer Treatment with Dr. Christopher Booth

2025-08-1130:11

Amivantamab + Lazertinib in 1st line Advanced EGFR + NSCLC - Mariposa

2025-06-0250:12

Claudin 18.2 - a SPOTLIGHT on Zolbetuximab - Part 2 of 2

2025-05-1639:42

Claudin 18.2 - a GLOW-ing biomarker in Gastric Cancer - Part 1 of 2

2025-05-0649:41

Take 2 Aspirin and call me in the morning - Adjuvant therapy for Colorectal Cancer

2025-03-2735:18

Resectable NSCLC: How to Choose the Right Treatment

2025-03-0345:35

2L Treatment of EGFR-Positive NSCLC

2025-02-1838:40

Belzutifan - A Spark of Light for Clear Cell Renal Cell Carcinoma

2025-01-3141:49

00:00

TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley

#box-pro-ellipsis-176592279663816{-webkit-line-clamp:2;}TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley

TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley

TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley